The “Smarter Monopoly” Debate Is Here—and It’s About to Reshape Drug Prices
For years, the pharmaceutical industry has lived under a familiar rulebook: patents reward innovation, exclusivity protects investment, and the market decides the rest. But a n…

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic Loss of Exclusivity
The “cliff” is coming—whether you’re ready or not.
In biologics, the moment a product loses exclusivity, the market doesn’…

Squeezing the Patent: How Drugmakers Use Reformulation to Outlast Generics
The patent clock is supposed to be destiny. Once it runs out, generics arrive—competition, lower prices, and a reset for patients and payers.
But in today’s pharmaceutical lands…

Patients aren’t asking “about patents.” They’re asking: “Will I be able to get my medicine?”
If you’ve spent any time reading what people search online, you’ll notice something striking: most “drug switching” questions aren’t really about chemistry or …

Evergreen the brand. Beat the generic. Repeat.
That’s the playbook many pharma companies have used for years—stacking “minor” patent changes, new formulations, new methods of use, and jurisdiction-by-jurisdiction filings to extend exclusivity and delay…

GPT, Rosalind, and the Generic Drug Question: What OpenAI’s Life Sciences Bet Really Changes
The hook: The most important part of OpenAI’s life sciences push may not be the model itself—it’s what it signals about how fast generic drug development could…

Patent cliffs don’t just happen—they’re engineered. And the companies that win the next phase of growth aren’t waiting for loss of exclusivity. They’re building payer strategy campaigns before the cliff hits.
In the pharma world, the “patent cliff” is …

OpenAI’s GPT just did something that should make pharma lawyers sit up: it reportedly “smashed drug patent cliffs” by helping generate new drug candidates and accelerate R&D—at a pace that’s being described as up to 70x faster than traditional appr…

Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
In pharma, the most expensive surprises rarely arrive with a press release. They arrive quietly—months before launch—when a competitor files a Paragraph IV c…

Your drug’s “patent life” isn’t one number in the GCC—it’s a moving target. Here’s how to know exactly what you’re up against.
If you’re a pharma leader, you already know the headline: patent protection is time-limited. But in the GCC, the real questio…